Hepatitis C Drug From Vertex Sails Through Test
May 2, 2011
On Thursday, Vertex Pharmaceutical's new hepatitis C virus treatment gained unanimous support from an independent committee that advises the Food and Drug Administration on antiviral drugs. After a daylong hearing with stakeholders, the committee of medical experts voted 18-0 to recommend FDA approve telaprevir as a new HCV treatment. FDA typically follows the panel's advice and is scheduled to make a decision on May 23.
Telaprevir is administered in combination with standard therapy: pegylated interferon and ribavirin. Of treatment-naïve HCV patients taking the telaprevir combination regimen, 79 percent achieved a sustained virologic response. Standard treatment alone against the same hardest-to-treat HCV strain typically achieves SVR in less than half of patients. Telaprevir works by blocking the protease enzyme HCV needs to replicate.
04.29.2011; Robert Weisman
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)